Adlai Nortye Ltd. (" Adlai Nortye ") was officially listed on NASDAQ on September 29, 2023 under the stock symbol "ANL". This means that Adlai Nortye has become the first Chinese company to successfully IPO in the United States since the official implementation of the new regulations on March 31 this year.

 

Adlai Nortye is a Phase III biotech company developing a variety of cancer immunotherapies. The company has built a global product pipeline through "co-innovation" and "in-house development" models, which currently covers more than 10 anti-tumor drug candidates.

 

The intermediary team for this IPO includes:

Cantor Fitzgerald and CLSA are co-sponsors;

Han Kun Law Offices and O’Melveny & Myers LLP are the company's PRC lawyers and the company's US lawyers;

Zhong Lun Law Firm and Latham & Watkins LLP are the underwriters’ PRC lawyers and the underwriters’ US lawyers;

Mazars USA LLP is the auditor.